Clinical trial
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT02719613 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 15, 2016
- Completion date
- February 23, 2026
- Enrollment
- 67 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.